The expression of activation-specific genes (IFNG, GZMB, and TNFRSF9) and cell proliferation-specific genes (IL2, IL2RA, and CD28) decreased with the increasing rounds of tumor stimulation (Figure 1C), especially from round 2 (the round in which tumor-killing ability begins to decline). The gene discussed is CD28; the disease is neoplasm.